Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Non-Current Debt (2016 - 2025)

IGC Pharma has reported Non-Current Debt over the past 14 years, most recently at $132000.0 for Q3 2025.

  • Quarterly Non-Current Debt fell 2.22% to $132000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $132000.0 through Sep 2025, down 2.22% year-over-year, with the annual reading at $134000.0 for FY2025, 2.19% down from the prior year.
  • Non-Current Debt was $132000.0 for Q3 2025 at IGC Pharma, down from $133000.0 in the prior quarter.
  • Over five years, Non-Current Debt peaked at $276000.0 in Q1 2021 and troughed at $132000.0 in Q3 2025.
  • The 5-year median for Non-Current Debt is $140000.0 (2023), against an average of $146473.7.
  • Year-over-year, Non-Current Debt crashed 76.67% in 2021 and then fell 2.08% in 2023.
  • A 5-year view of Non-Current Debt shows it stood at $145000.0 in 2021, then decreased by 2.76% to $141000.0 in 2022, then decreased by 2.13% to $138000.0 in 2023, then fell by 2.9% to $134000.0 in 2024, then fell by 1.49% to $132000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Non-Current Debt are $132000.0 (Q3 2025), $133000.0 (Q2 2025), and $134000.0 (Q1 2025).